bullish
Daiichi Sankyo - Downside Limited from Here
189 Views24 Feb 2017 14:43
With Effient (prasugrel, antiplatelet) and Savaysa (edoxaban, anti-coagulant), Daiichi Sankyo looked relatively well prepared to see through the...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 16-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Daiichi Sankyo (4568 JP) Releases Phase I Data for DS-8201 at ESMO 201714 Sep 2017
- Did AstraZeneca Really Bid for Daiichi Sankyo, Did Daiichi Sankyo Really Turn Them Down?04 Sep 2017
- Daiichi Sankyo (4568) - Is Luck Running Out?10 Jul 2017
- Daiichi Sankyo - Downside Limited from Here24 Feb 2017
x